Using synthetic nanoparticles to improve tuberculosis treatment by targeting immune cells
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-10888212
This study is looking at how tiny particles mixed with antibodies can help improve tuberculosis treatment by targeting certain immune cells that make it harder for your body to fight the infection, so you might get better results from your treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10888212 on ClinicalTrials.gov |
What this research studies
This research investigates how synthetic nanoparticles combined with antibodies can deplete specific immune cells that hinder effective tuberculosis (TB) treatment. By understanding the role of myeloid-derived suppressor cells (MDSCs) in TB, the study aims to enhance the immune response against the Mycobacterium tuberculosis bacteria. The approach involves using host-directed therapies alongside traditional antibiotics to improve patient outcomes. Patients may benefit from a more effective treatment regimen that addresses both the infection and the immune suppression caused by MDSCs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis who are experiencing challenges in treatment response.
Not a fit: Patients who do not have tuberculosis or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with tuberculosis by enhancing their immune response.
How similar studies have performed: Previous research has shown promise in using immunomodulatory therapies to enhance treatment for tuberculosis, indicating that this approach may be viable.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RENGARAJAN, JYOTHI — EMORY UNIVERSITY
- Study coordinator: RENGARAJAN, JYOTHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.